Company profile
Ticker
VERA
Exchange
Website
CEO
Dr. Marshall W. Fordyce M.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Wealthbridge Acquisition Ltd
SEC CIK
Corporate docs
IRS number
812744449
VERA stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
13 Jan 25
10-Q
2024 Q3
Quarterly report
7 Nov 24
8-K
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
7 Nov 24
8-K
Other Events
31 Oct 24
424B5
Prospectus supplement for primary offering
30 Oct 24
424B5
Prospectus supplement for primary offering
29 Oct 24
8-K
Results of Operations and Financial Condition
28 Oct 24
S-3ASR
Automatic shelf registration
28 Oct 24
8-K
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
2 Oct 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
Latest ownership filings
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 25
4
Marshall Fordyce
10 Jan 25
144
Notice of proposed sale of securities
8 Jan 25
4
Marshall Fordyce
20 Dec 24
144
Notice of proposed sale of securities
18 Dec 24
4
Marshall Fordyce
13 Dec 24
144
Notice of proposed sale of securities
11 Dec 24
4
Marshall Fordyce
27 Nov 24
144
Notice of proposed sale of securities
25 Nov 24
4
Jason S Carter
20 Nov 24
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 27.26 mm | 27.26 mm | 27.26 mm | 27.26 mm | 27.26 mm | 27.26 mm |
Cash burn (monthly) | (no burn) | 552.75 k | 16.60 mm | 11.33 mm | 12.30 mm | 7.06 mm |
Cash used (since last report) | n/a | 2.58 mm | 77.55 mm | 52.92 mm | 57.44 mm | 32.98 mm |
Cash remaining | n/a | 24.67 mm | -50.29 mm | -25.66 mm | -30.18 mm | -5.73 mm |
Runway (months of cash) | n/a | 44.6 | -3.0 | -2.3 | -2.5 | -0.8 |
Institutional ownership, Q3 2024
96.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 175 |
Opened positions | 27 |
Closed positions | 25 |
Increased positions | 68 |
Reduced positions | 51 |
13F shares | Current |
---|---|
Total value | 2.11 tn |
Total shares | 61.03 mm |
Total puts | 155.90 k |
Total calls | 134.40 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Avoro Capital Advisors | 4.31 mm | $190.48 bn |
T. Rowe Price | 3.94 mm | $174.11 mm |
BlackRock | 3.45 mm | $152.59 bn |
Longitude Capital Partners IV | 3.43 mm | $130.34 mm |
Sofinnova Investments | 2.79 mm | $123.49 bn |
Sofinnova Venture Partners X | 2.79 mm | $114.55 mm |
FMR | 2.79 mm | $123.11 bn |
Vanguard | 2.58 mm | $114.04 bn |
Commodore Capital | 2.48 mm | $109.40 bn |
Eversept Partners | 2.05 mm | $90.62 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Jan 25 | Marshall Fordyce | Class A Common Stock | Sell | Dispose S | No | Yes | 42 | 1,875 | 78.75 k | 143,603 |
8 Jan 25 | Marshall Fordyce | Class A Common Stock | Option exercise | Acquire M | No | No | 2.8968 | 1,875 | 5.43 k | 145,478 |
8 Jan 25 | Marshall Fordyce | Class A Common Stock | Sell | Dispose S | No | Yes | 42.0334 | 5,650 | 237.49 k | 143,603 |
8 Jan 25 | Marshall Fordyce | Class A Common Stock | Option exercise | Acquire M | No | No | 2.8968 | 5,650 | 16.37 k | 149,253 |
8 Jan 25 | Marshall Fordyce | Class A Common Stock | Sell | Dispose S | No | Yes | 41.5335 | 9,975 | 414.30 k | 143,603 |
8 Jan 25 | Marshall Fordyce | Class A Common Stock | Option exercise | Acquire M | No | No | 2.8968 | 9,975 | 28.90 k | 153,578 |
8 Jan 25 | Marshall Fordyce | Stock Option Class A Common Stock | Option exercise | Dispose M | No | No | 2.8968 | 1,875 | 5.43 k | 609,051 |
8 Jan 25 | Marshall Fordyce | Stock Option Class A Common Stock | Option exercise | Dispose M | No | No | 2.8968 | 15,625 | 45.26 k | 610,926 |
19 Dec 24 | Marshall Fordyce | Class A Common Stock | Option exercise | Acquire M | No | No | 2.8968 | 57,661 | 167.03 k | 143,603 |
19 Dec 24 | Marshall Fordyce | Stock Option Class A Common Stock | Option exercise | Dispose M | No | No | 2.8968 | 57,661 | 167.03 k | 626,551 |
News
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
2w ago
Wolfe Research Initiates Coverage On Vera Therapeutics with Outperform Rating, Announces Price Target of $49
2w ago
Top 3 Health Care Stocks That Could Blast Off This Quarter
3w ago
What's Going On With Vera Therapeutics Stock?
1mo ago
Wells Fargo Initiates Coverage On Vera Therapeutics with Overweight Rating, Announces Price Target of $70
2mo ago
Press releases
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1mo ago
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
1mo ago
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
1mo ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2mo ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2mo ago